Potential repurposing of the HDAC inhibitor valproic acid for patients with COVID-19
Sign Up to like & getrecommendations! Published in 2021 at "European Journal of Pharmacology"
DOI: 10.1016/j.ejphar.2021.173988
Abstract: There is a need for therapeutic approaches to prevent and mitigate the effects of Coronavirus Disease 2019 (COVID-19). The histone deacetylase (HDAC) inhibitor valproic acid, which has been available for the therapy of epilepsy for… read more here.
Keywords: hdac inhibitor; acid; inhibitor valproic; valproic acid ... See more keywords